Table 2.
Some clinical subgroups are associated with increased or decreased performance of the primary site classifiers PM and PM + CN
| PM | PM + CN | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Primary site | Subgroup | Acc. (%) | N | P | Acc. (%) | N | P | ||
| Subtype | |||||||||
| Breast | ER | 64 | 417 | 0.064 | 91 | 416 | 0.00033 | ** | |
| HER2 | 63 | 146 | 0.31 | 91 | 138 | 0.037 | * | ||
| TNBC | 27 | 98 | 4.1 × 109 | ** | 40 | 97 | 3.3 × 1018 | ** | |
| Endometrium | MSI | 77 | 71 | 0.015 | * | 93 | 70 | 3 × 105 | ** |
| MSS | 54 | 157 | 0.17 | 59 | 156 | 0.038 | * | ||
| Large intestine | MSI | 97 | 68 | 0.091 | 74 | 68 | 8.6 × 105 | ** | |
| MSS | 88 | 233 | 0.48 | 97 | 230 | 0.0075 | ** | ||
| Ovary | mBRCA1 | 76 | 55 | 0.097 | 96 | 55 | 0.56 | ||
| mBRCA2 | 79 | 39 | 0.077 | 97 | 38 | 0.5 | |||
| wtBRCA | 61 | 338 | 0.29 | 92 | 333 | 0.58 | |||
| Stage | |||||||||
| Breast | Stage I | 65 | 129 | 0.24 | 82 | 127 | 0.6 | ||
| Stage II | 59 | 437 | 0.95 | 84 | 432 | 0.93 | |||
| Stage III | 57 | 175 | 0.55 | 84 | 172 | 1 | |||
| Stage IV | 47 | 15 | 0.43 | 87 | 15 | 1 | |||
| Kidney | Stage I | 80 | 153 | 0.8 | 95 | 149 | 1 | ||
| Stage II | 81 | 32 | 1 | 91 | 32 | 0.44 | |||
| Stage III | 81 | 78 | 0.87 | 97 | 77 | 0.39 | |||
| Stage IV | 88 | 43 | 0.39 | 88 | 42 | 0.18 | |||
| Large intestine | Stage I | 89 | 65 | 0.82 | 94 | 64 | 1 | ||
| Stage II | 90 | 143 | 0.87 | 91 | 141 | 0.45 | |||
| Stage III | 89 | 101 | 0.85 | 93 | 101 | 1 | |||
| Stage IV | 94 | 49 | 0.6 | 98 | 49 | 0.35 | |||
| Lung | Stage I | 79 | 261 | 0.7 | 82 | 257 | 0.53 | ||
| Stage II | 78 | 106 | 0.69 | 84 | 105 | 0.88 | |||
| Stage III | 87 | 97 | 0.16 | 89 | 95 | 0.27 | |||
| Stage IV | 74 | 19 | 0.56 | 89 | 18 | 1 | |||
| Grade | |||||||||
| Endometrium | G1 | 74 | 76 | 0.055 | 88 | 76 | 0.0022 | ** | |
| G2 | 73 | 75 | 0.073 | 86 | 73 | 0.0088 | ** | ||
| G3 | 41 | 92 | 0.0013 | ** | 45 | 92 | 1.2 × 105 | ** | |
| Kidney | G1 | 71 | 7 | 0.61 | 100 | 7 | 1 | ||
| G2 | 84 | 128 | 0.68 | 93 | 125 | 0.66 | |||
| G3 | 80 | 122 | 0.68 | 96 | 120 | 0.63 | |||
| G4 | 82 | 45 | 1 | 93 | 44 | 0.73 | |||
| Ovary | G1 | 0 | 3 | 0.056 | 33 | 3 | 0.014 | * | |
| G2 | 60 | 55 | 0.77 | 87 | 54 | 0.098 | |||
| G3 | 63 | 405 | 0.83 | 95 | 394 | 0.47 | |||
| G4 | 0 | 1 | 0.38 | 100 | 1 | 1 | |||
Information on subtype, grade and stage were retrieved from TCGA, and are therefore not available for all tumors in the COSMIC database. ER estrogen receptor positive. HER2 human epidermal growth factor receptor 2 positive. TNBC triple negative breast cancer. MSI microsatellite instability. MSS microsatellite stable. mBRCA1 mutated BRCA1. mBRCA2 mutated BRCA2. wtBRCA wildtype BRCA1 and BRCA2. Acc. accuracy ie. the percentage of tumors correctly classified. N the number of tumors in subgroup. P p-value from Fisher’s exact test comparing accuracy among samples in or not in each subgroup. *p < 0.05. **p < 0.01